
Opinion|Videos|December 16, 2024
Exploring DMTs: Blood-Brain Barrier Penetration and Cognitive Health Benefits
Author(s)Gabriel Pardo, MD, FAAN, Martin Belkin, DO
Key Takeaways
- Fingolimod, siponimod, and natalizumab can penetrate the blood-brain barrier, potentially impacting brain health directly.
- The impact of DMTs on cognitive health is under investigation, with some evidence suggesting benefits in slowing cognitive decline.
Panelists discuss how disease-modifying therapies (DMTs) like dimethyl fumarate, fingolimod, and cladribine demonstrate potential blood-brain barrier penetration, offering neuroprotective mechanisms. While these therapies show promise in mitigating cognitive decline, their impacts vary, highlighting the complex interplay among neuroinflammation, immune modulation, and cognitive preservation in multiple sclerosis management.
Advertisement
Video content above is prompted by the following:
- Which of the DMTs can penetrate the blood-brain barrier and have the potential to impact brain health directly?
- What is our understanding of the impact of various DMTs on cognitive health?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tau PET Tracer MK-6240 for Alzheimer Diagnostic Workup
2
FDA Clears Phase 2 Trial for Demyelinating Agent Lucid-MS in Progressive Multiple Sclerosis
3
Zoster Vaccine Shows Strong Effectiveness in Patients With Multiple Sclerosis
4
Voyager to Advance 2 Tau-Targeted Alzheimer Therapies Toward Key Clinical Milestones
5


















